跳转至内容
Merck
CN

850103P

Avanti

莱索托时间 17:1

Avanti Research™ - A Croda Brand

别名:

PI(17:1(10Z)/0:0); 110718

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C26H52NO12P
CAS Number:
1246353-39-8
分子量:
601.66
UNSPSC代码:
51191904
NACRES:
NA.25

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

莱索托时间 17:1, 1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder

方案

>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)

表单

powder

包装

pkg of 1 × 100 μg (with stopper and crimp cap (850103P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850103P-500ug))

制造商/商品名称

Avanti Research™ - A Croda Brand 850103P

脂质类型

phosphoglycerides

运输

dry ice

储存温度

−20°C

SMILES字符串

[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCC/C=C\CCCCCC)=O.[NH4+]

InChI

1S/C26H49O12P.H3N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(28)36-17-19(27)18-37-39(34,35)38-26-24(32)22(30)21(29)23(31)25(26)33;/h7-8,19,21-27,29-33H,2-6,9-18H2,1H3,(H,34,35);1H3/b8-7-;/t19-,21-,22-,23+,24-,25-,26-;/m1./s1

InChI key

VFLBJIAFDLNWCY-SNLSZFGJSA-N

相关类别

一般描述

溶血磷脂酰肌醇（LPI）是磷脂酰肌醇（PI）的降解产物，是一种溶血磷脂亚种，在其头基中带有肌醇。

应用

17:1 Lyso PI（1-（10Z-十七碳烯酰基）-2-羟基-sn-甘油-3-磷酸-（1′-肌醇））已用作小鼠脑脂质组学LC-MS的内标。它可以用作内标，用于使用高效液相色谱/电喷雾电离串联质谱法（HPLC/ESI-MS）分析小鼠中的溶血磷脂酰肌醇（LPI），并使用液相色谱串联质谱（LC-MS-MS）系统检测定量分析慢性高脂饮食（HFD）喂养的WT和KO小鼠肝脏中的lysoPI（LPI）。

生化/生理作用

L-α-溶血磷脂酰肌醇（LPI）循环水平的升高与癌症相关，而且LPI是G蛋白偶联受体GPR55的有效配体。
溶血磷脂酰肌醇（LPI）充当生物活性溶血磷脂介体。它有利于静止的成纤维细胞的促有丝分裂活性。LPI具有在前脑缺血情况下区组海马神经元死亡的能力。

包装

带塞子和压接盖的2 mL棕色血清瓶（850103P-100ug）
带塞子和压接盖的2 mL棕色血清瓶（850103P-500ug）

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

No data available

闪点(°C)

No data available

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Atsushi Yamashita et al.
Prostaglandins & other lipid mediators, 107, 103-116 (2013-05-30)
Lysophosphatidylinositol (LPI) is a subspecies of lysophospholipid and is assumed to be not only a degradation product of phosphatidylinositol (PI), but also a bioactive lysophospholipid mediator. However, not much attention has been directed toward LPI compared to lysophosphatidic acid (LPA)
Julien Masquelier et al.
Journal of pharmaceutical and biomedical analysis, 126, 132-140 (2016-05-22)
Increasing evidence suggests that lysophosphatidylinositols (LPIs), a subspecies of lysophospholipids, are important endogenous mediators. Although LPIs long remained among the less studied lysophospholipids, the identification of GPR55 as their molecular target sparked a renewed interest in the study of these
Tsukasa Yagi et al.
Cancers, 12(1) (2020-01-01)
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer
Jordon M Inloes et al.
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持